Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy

BACKGROUND: Chemotherapy-induced neutropenia is a common result of myelosuppressive chemotherapy treatment. Infections such as febrile neutropenia (FN) are sensitive to the duration of neutropenia as well as the depth of absolute neutrophil count (ANC) at nadir. Filgrastim, a granulocyte colony stim...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Kalpna, Misra, Priya, Kher, Sanyukta, Shah, Nirmesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127997/
https://www.ncbi.nlm.nih.gov/pubmed/30202638
http://dx.doi.org/10.1186/s40164-018-0114-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127997/
https://www.ncbi.nlm.nih.gov/pubmed/30202638
http://dx.doi.org/10.1186/s40164-018-0114-9

Ejemplares similares